SMTI
$19.62
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers Cellera...
Recent News
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates
Evolus (EOLS) delivered earnings and revenue surprises of 0.00% and +0.98%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Shareholders in Sanara MedTech (NASDAQ:SMTI) are in the red if they invested three years ago
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
Sanara MedTech (SMTI) Upgraded to Strong Buy: Here's What You Should Know
Sanara MedTech (SMTI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Sanara MedTech (SMTI) Is Refocusing After Discontinuing THP Division and Reporting Quarterly Losses
Sanara MedTech announced the discontinuation of its Tissue Health Plus (THP) division and reported third-quarter earnings, with sales reaching US$26.33 million and a net loss of US$30.41 million for the period ended September 30, 2025. This move marks a business realignment to concentrate on the core surgical segment, with management expecting THP wind-down costs to conclude by the end of 2025 and further resource shifts to support main operations. We’ll explore how the decision to exit THP...
Sanara MedTech (SMTI): Assessing Valuation After Strategic Shift and Quarterly Earnings Beat
Sanara MedTech (SMTI) just reported a shakeup in its business model by winding down its Tissue Health Plus division while also topping quarterly earnings estimates. Investors are watching to see how this dual move shapes future performance. See our latest analysis for Sanara MedTech. Sanara MedTech’s decision to exit its Tissue Health Plus segment and its recent earnings surprise have coincided with a sharp loss of momentum in the stock, as reflected by a 29.6% 1-month share price return and...